Daiichi Sankyo Company, Limited (DSKYF)
OTCMKTS
· Delayed Price · Currency is USD
19.11
+1.27 (7.13%)
Mar 9, 2026, 2:57 PM EST
Daiichi Sankyo Company Revenue
Daiichi Sankyo Company had revenue of 558.11B JPY in the quarter ending December 31, 2025, with 15.11% growth. This brings the company's revenue in the last twelve months to 2.05T, up 14.26% year-over-year. In the fiscal year ending March 31, 2025, Daiichi Sankyo Company had annual revenue of 1.89T with 17.77% growth.
Revenue (ttm)
2,052.15B JPY
Revenue Growth
+14.26%
P/S Ratio
2.55
Revenue / Employee
103.83M JPY
Employees
19,765
Market Cap
33.40B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1,886.26B | 284.57B | 17.77% |
| Mar 31, 2024 | 1,601.69B | 323.21B | 25.28% |
| Mar 31, 2023 | 1,278.48B | 233.59B | 22.36% |
| Mar 31, 2022 | 1,044.89B | 82.38B | 8.56% |
| Mar 31, 2021 | 962.52B | -19.28B | -1.96% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Elite Pharmaceuticals | 140.12M |
| American Oncology Network | 1.76B |
| Northwest Biotherapeutics | 937.00K |
| Silence Therapeutics | 559.00K |
| Tian'an Technology Group | 2.12M |
| Vaxart | 148.20M |
Daiichi Sankyo Company News
- 4 days ago - GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe. - Business Wire
- 14 days ago - SylamoreBio Announces Research Collaboration With Daiichi Sankyo to Advance SyLEC™ Delivery Technology - Business Wire
- 17 days ago - Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&D - Business Wire
- 20 days ago - BostonGene Announces Strategic Collaboration with Daiichi Sankyo to Accelerate Drug Development Through AI-Driven Multimodal Analytics - Business Wire
- 4 weeks ago - DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo - Business Wire
- 6 weeks ago - Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe - Business Wire
- 6 weeks ago - Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology - PRNewsWire
- 2 months ago - Organon Enters into a Commercialization Agreement for Daiichi Sankyo's Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway - Business Wire